Atara Biotherapeutics (ATRA) News Today $6.57 -1.26 (-16.09%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Atara Biotherapeutics price target lowered to $17 from $21 at CanaccordJanuary 18 at 8:59 AM | markets.businessinsider.comBuy Rating for Atara Biotherapeutics Driven by Manufacturing Resolution and Strategic InitiativesJanuary 18 at 8:59 AM | markets.businessinsider.comAtara Bio reiterated at Buy by Canaccord on expected Ebvallo manufactureJanuary 17 at 5:55 PM | msn.comAtara Shares Sink After FDA Stalls Cancer TreatmentJanuary 16 at 7:37 PM | marketwatch.comAtara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO ApplicationJanuary 16 at 2:37 PM | sg.finance.yahoo.comAtara announces Ebvallo CRL did not find clinical efficacy deficienciesJanuary 16 at 2:37 PM | markets.businessinsider.comAtara Biotherapeutics trading halted, news pendingJanuary 16 at 2:37 PM | markets.businessinsider.comAtara stock plummets on FDA setback for EBV drugJanuary 16 at 9:34 AM | in.investing.comFDA Rejects Atara's Request to Bring Blood Cancer Treatment to MarketJanuary 16 at 9:34 AM | marketwatch.comAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)January 16 at 9:34 AM | stockhouse.comUS FDA declines to approve Atara Biotherapeutics' cancer therapyJanuary 16 at 8:41 AM | reuters.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $18.75 Consensus Price Target from AnalystsJanuary 10, 2025 | americanbankingnews.comAtara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last weekJanuary 8, 2025 | finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by BrokeragesAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assignedJanuary 7, 2025 | marketbeat.comBiotech Stocks Facing FDA Decision In January 2025January 1, 2025 | markets.businessinsider.comAtara Biotherapeutics, Inc. Common Stock (ATRA) Insider ActivityDecember 25, 2024 | nasdaq.comAtara Biotherapeutics (NASDAQ:ATRA) Raised to Strong-Buy at RODMAN&RENSHAWRODMAN&RENSHAW upgraded shares of Atara Biotherapeutics to a "strong-buy" rating in a report on Friday.December 21, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Atara Biotherapeutics (ATRA) with Buy RecommendationDecember 20, 2024 | msn.comAtara Biotherapeutics (NASDAQ:ATRA) Earns Buy Rating from Analysts at Rodman & RenshawRodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday. They set a "buy" rating and a $25.00 price objective for the company.December 20, 2024 | marketbeat.comRajani DinavahiDecember 15, 2024 | latimes.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by AnalystsShares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, oneDecember 13, 2024 | marketbeat.comCentiva Capital LP Sells 96,847 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)Centiva Capital LP lowered its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 69.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,403 shares of the biotechnologDecember 10, 2024 | marketbeat.comAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx ConferenceNovember 27, 2024 | businesswire.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $11,200.00 in StockNovember 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of "Hold" by BrokeragesShares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been given a consensus rating of "Hold" by the four analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommNovember 18, 2024 | marketbeat.comEcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics IncNovember 15, 2024 | gurufocus.comAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceNovember 13, 2024 | businesswire.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group boosted their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday.November 13, 2024 | marketbeat.comInsights into Atara Biotherapeutics's Upcoming EarningsNovember 11, 2024 | benzinga.comAtara Biotherapeutics (ATRA) to Release Earnings on TuesdayAtara Biotherapeutics (NASDAQ:ATRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comAtara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comAtara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?September 4, 2024 | msn.comAtara Biotherapeutics Shares Climb on $36 Million Direct OfferingSeptember 3, 2024 | marketwatch.comAtara Biotherapeutics Announces $36 Million Registered Direct OfferingSeptember 3, 2024 | finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $12,073.23 in StockAugust 21, 2024 | insidertrades.comAtara Biotherapeutics (ATRA) Gets a Hold from Stifel NicolausAugust 19, 2024 | markets.businessinsider.comMizuho Upgrades Atara Biotherapeutics (ATRA)August 17, 2024 | msn.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 15, 2024 | uk.finance.yahoo.comAtara Biotherapeutics Second Quarter 2024 Earnings: Misses ExpectationsAugust 14, 2024 | finance.yahoo.comATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | msn.comTSX inches up; investors cautious ahead of US dataAugust 12, 2024 | msn.comStock market today: Nasdaq edges higher, Dow drops as investors await key signals on inflation, economyAugust 12, 2024 | ca.finance.yahoo.comNickelodeon Marketing Exec Sabrina Caluori Exiting Ahead Of Broader Paramount LayoffsAugust 12, 2024 | nz.finance.yahoo.comAtara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership UpdateAugust 12, 2024 | finance.yahoo.comAtara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceAugust 7, 2024 | finance.yahoo.comAtara Biotherapeutics Inc (ATRA) Earnings Dates & ReportsAugust 6, 2024 | investing.comAtara Biotherapeutics, Inc. (AT20.F)August 5, 2024 | uk.finance.yahoo.comAT20.MU,0P0001LALG,0 (AT20.MU)August 4, 2024 | uk.finance.yahoo.comAtara Biotherapeutics (NASDAQ:ATRA) Stock, Short Interest ReportAugust 1, 2024 | benzinga.com Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Media Mentions By Week ATRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼-0.270.44▲Average Medical News Sentiment ATRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼132▲ATRA Articles Average Week Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AURA News KALV News ORGO News VALN News ETON News PRME News ENGN News KRRO News RGNX News GLUE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts